Last update: Aug. 17, 2019

Frovatriptan

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack.
Oral administration in a daily dose.

Since the last update we have not found published data on its excretion in breastmilk.

Several expert authors consider its use to be safe or probably safe during breastfeeding (Hale 2019, Briggs 2017, Amundsen 2015, Duong 2010).

Its use, usually in isolated doses, makes the occurrence of adverse effects in infants unlikely (Jürgens 2009).

As there is less published data than for other drugs in the same group, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Frovatriptan is also known as


Frovatriptan in other languages or writings:

Group

Frovatriptan belongs to this group or family:

Tradenames

Main tradenames from several countries containing Frovatriptan in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 22 - 30 %
Molecular weight 379 daltons
Protein Binding 15 %
VD 3 - 4 l/Kg
pKa 10,4 -
Tmax 2 - 3 hours
T1/2 26 hours

References

  1. Hale TW. Hale's Medications & Mothers' Milk. Springer Publishing Company. 2019
  2. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. 11th edition (acces on line) 2017
  3. Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015 Apr;11(4):209-19. Review. Abstract
  4. AEMPS-Menarini Frovatriptán (Forvey). Ficha técnica. 2014 Full text (in our servers)
  5. Duong S, Bozzo P, Nordeng H, Einarson A. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010 Abstract Full text (link to original source) Full text (in our servers)
  6. Jürgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia. 2009 Abstract
  7. FDA-Endo. Frovatriptan (Frova). Drug Summary. 2007 Full text (in our servers)
  8. Balbisi EA. Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Abstract Full text (in our servers)
  9. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Abstract

Total visits

2,793

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM